Sort
10,766 grants matching “checkpoint inhibitor”
Flt3l gene-modified cDC1 in situ vaccination in NSCLC: mechanisms and therapeutic application
$0Ramin Salehi-Rad · Va Greater Los Angeles Healthcare System · IK2 · FY2024 · VA
Epigenetic Regulation of Immune Evasion in Bladder Cancer
$0Joshua James Meeks · Jesse Brown Va Medical Center · I01 · FY2024 · VA
Muscarinic Receptors Regulate Colon Cancer Stem Cell Function and Invasiveness
$0Jean-Pierre Raufman · Baltimore Va Medical Center · I01 · FY2024 · VA
To Elucidate the Biological Function and Translational Potential of NLRP3 in Immunotherapy-resistant Melanoma
$0Carlo Marchetti · Va Eastern Colorado Health Care System · IK2 · FY2024 · VA
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
$0Matthew B Rettig · Va Greater Los Angeles Healthcare System · I01 · FY2024 · VA
Role of IL-33 in KRAS and STK11 mutant non-small cell lung cancer
$0Harold H Bien · Northport Va Medical Center · I01 · FY2025 · VA
Role of MIF-CD74 signaling as an immune regulator and therapy target in pancreas cancer.
$0Ravikanth Maddipati · Va North Texas Health Care System · I01 · FY2025 · VA
DC-HIL in cancer
$0Ponciano D Cruz · Va North Texas Health Care System · I01 · FY2019 · VA
Defining the role of the EGFR in MHC expression and anti-tumor immune responses.
$0Brian P Pollack · Veterans Health Administration · I01 · FY2018 · VA
DNA Repair and Cell Cycle Checkpoints as Targets for Ant
$0Basic Sciences · Z01 · FY2002 · BC
Lung Dysbiosis and Increased Host Susceptibility to Respiratory Pathogens
$0Benjamin G Wu · Va Medical Center · IK2 · FY2023 · VA
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy
$0Eric T. Kimchi · Harry S. Truman Memorial Va Hospital · I01 · FY2020 · VA
Genes Involved in Cellular Differ.n and Proliferation
$0Clinical Sciences · Z01 · FY2004 · SC
Overcoming BRAF and MEK Inhibitors Resistance in Advanced Melanoma
$0Niramol Savaraj · Miami Va Health Care System · I01 · FY2018 · VA
Preclinical investigation of PI3K inhibition and immune checkpoint blockade combination therapy for treatment of Merkel cell carcinoma using humanized mouse models
$0Ling Gao · Veterans Health Administration · I01 · FY2020 · VA
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer
$0Steven M. Dubinett · Va Greater Los Angeles Healthcare System · I01 · FY2019 · VA
Role of ATRX, a chromatin remodeler, in immunotherapy response
$0Daniel Sanghoon Shin · Va Greater Los Angeles Healthcare System · I01 · FY2025 · VA
DC-HIL in cancer
$0Ponciano D Cruz · Va North Texas Health Care System · I01 · FY2025 · VA
Lung Dysbiosis and Increased Host Susceptibility to Respiratory Pathogens
$0Benjamin G Wu · Va Medical Center · IK2 · FY2025 · VA
Type I Interferon Regulation of PD-L1 Expression and Function in MDSCs
$0Kebin Liu · Charlie Norwood Va Medical Center · I01 · FY2019 · VA
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy
$0Eric T. Kimchi · Harry S. Truman Memorial Va Hospital · I01 · FY2021 · VA
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy
$0Eric T. Kimchi · Harry S. Truman Memorial Va Hospital · I01 · FY2019 · VA
Targeting Integrins in Lung Cancer
$0Tianhong Li · Va Northern California Health Care Sys · I01 · FY2022 · VA
Assessment of cardiotoxicity in Immunity Checkpoint Blockers and other cancer therapies
$0Mary Susan Vaughan Sarrazin · Iowa City Va Medical Center · I21 · FY2022 · VA
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
$0Ann Richmond · Veterans Health Administration · IK6 · FY2020 · VA